Endogenous Mitochondria Resistance to Acute Kidney Injury

描述(由申请人提供)： 急性肾损伤(AKI)发生在所有住院患者中的5%-7%，最近的证据表明，即使是微小的肾功能变化也会增加死亡风险。在ICU，AKI与50%的死亡率有关，这一统计数据甚至在透析治疗中也没有改变。事实上，由VA和NIH赞助的联合透析剂量研究--急性肾功能衰竭试验网络研究--在比较透析剂量时，死亡率统计没有变化。显然，迫切需要新的方法来解决这种威胁生命的疾病。鉴于退伍军人管理局人口老龄化，容易患糖尿病和高血压，AKI是这一群体的主要健康问题。在完成这项VA功绩评估后，肾病界的研究人员将在小分子药物发现方面有新的靶点，这应该会改善与AKI相关的死亡率。

DESCRIPTION (provided by applicant): Acute kidney injury (AKI) occurs in 5-7% of all hospital admissions and recent evidence has shown that even minor changes in renal function are associated with increased risk of death. In the ICU, AKI is associated with 50% mortality, a statistic which has not changed even with dialysis therapy. In fact the Acute Renal Failure Trial Network study, a combined VA and NIH sponsored dialysis dosing study, showed no change in mortality statistics when comparing dialysis dosing. Clearly new approaches are urgently needed to address this life-threatening disease. Given the fact that the VA population is aging, prone to diabetes and hypertension, AKI is a major health problem in this group. Upon completion of this VA Merit Review, investigators in the renal community will have new targets for small molecular drug discovery that should ameliorate the mortality associated with AKI.